New study tests online therapy to ease stress for parents of kids with RASopathies

NCT ID NCT05361811

Recruiting now Symptom relief Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests whether Acceptance and Commitment Therapy (ACT), delivered through a smartphone app, can help caregivers of children with RASopathies (like Neurofibromatosis type 1 and Noonan syndrome) cope with parenting stress. The trial is fully remote and involves 70 adult caregivers. Participants either start ACT right away or wait 8 weeks, then complete surveys and coaching sessions. The goal is to see if the therapy is feasible and reduces stress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acceptance and Commitment Therapy (ACT)
What this could lead to: If it works, this could provide a practical, remote therapy option to help caregivers manage stress and improve well-being.
What could go wrong: This is a small feasibility study (70 participants) with no blinding, so results may not be generalizable. The intervention is behavioral, not a medical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOFACIOCUTANEOUS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiofaciocutaneous syndrome Costello syndrome hereditary disease Legius syndrome neurofibromatosis type 1 Noonan syndrome RASopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOFACIOCUTANEOUS SYNDROME COSTELLO SYNDROME LEGIUS SYNDROME NEUROFIBROMATOSIS 1 NOONAN SYNDROME

Contacts and locations

Locations

National Cancer Institute (NCI)
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.